First‑Line Oral Bisphosphonate Selection for Postmenopausal Osteoporosis

Guideline Recommendations

• The American Family Physician guideline recommends oral bisphosphonates as the first‑line therapy for postmenopausal osteoporosis, with the specific agent chosen according to patient preference and gastrointestinal tolerance. 1
• The American Association of Clinical Endocrinologists/American College of Endocrinology states that alendronate, risedronate, zoledronate, and denosumab each have “broad‑spectrum” antifracture efficacy (spine, hip, and non‑vertebral sites) and should be considered initial options for eligible patients. 2

Efficacy Comparison

These data derive from a head‑to‑head clinical trial demonstrating superior BMD gains with alendronate. (Level II evidence) 3

• After up to 5 years of oral bisphosphonate therapy (or 3 years of intravenous therapy), a drug holiday is advised for patients at low‑to‑moderate fracture risk to lessen the chance of atypical femoral fractures. (Guideline recommendation) 3

Administration Requirements

• Both immediate‑release alendronate and risedronate must be taken on an empty stomach with 6–8 oz of plain water, followed by at least 30 minutes of upright posture before any food, drink, or other medication. (Guideline) 1
• Delayed‑release (gastro‑resistant) risedronate may be taken immediately after breakfast, eliminating the fasting requirement. (Guideline) 1

Pre‑Treatment Requirements

• Vitamin D deficiency should be corrected to a serum 25‑OH‑D level ≥ 30 ng/mL before starting any bisphosphonate to avoid severe hypocalcemia. (Guideline) 4
• Ensure a total calcium intake of about 1,200 mg per day from diet and supplements. (Guideline) 1
• Recommend vitamin D supplementation of 800–1,000 IU daily. (Guideline) 1

Safety and Monitoring

• After 5 years of oral bisphosphonate use (or 3 years of IV therapy), reassess fracture risk; continuing therapy in low‑to‑moderate risk patients increases the likelihood of atypical femoral fractures. (Guideline) 3

Clinical Decision Algorithm

• If the patient can reliably fast and remain upright: choose either alendronate 70 mg weekly or risedronate 35 mg weekly, guided by cost and availability. (Guideline) 1
• If the patient has upper‑GI symptoms, difficulty with fasting, or takes multiple morning medications: consider delayed‑release risedronate 35 mg weekly, which can be taken after breakfast. (Guideline) 1
• If the patient has esophageal disease, cannot stay upright for 30 minutes, active upper‑GI disease, or a creatinine clearance < 35 mL/min: switch to an injectable bisphosphonate (zoledronic acid 5 mg annually) or denosumab 60 mg subcutaneously every 6 months. (Guideline) 2
• If the patient is at very high fracture risk (multiple vertebral fractures, prior hip fracture, or T‑score < ‑3.0): initiate anabolic therapy (e.g., teriparatide, abaloparatide, or romosozumab) before transitioning to a bisphosphonate for consolidation. (Guideline) 2